Close Menu
  • Briefing
    • Cover Story
    • Latest News
    • Counties
  • Politics
    • Society
  • Special Reports
    • Companies
    • Enterprise
    • Money
    • Technology
  • Columns
  • Dispatches from China
  • Member Content
    • Shop
  • Contact Us
    • About us
Facebook X (Twitter) Instagram
Facebook X (Twitter) Instagram LinkedIn
Nairobi Business Monthly
Subscribe
  • Briefing
    • Cover Story
    • Latest News
    • Counties
  • Politics
    • Society
  • Special Reports
    • Companies
    • Enterprise
    • Money
    • Technology
  • Columns
  • Dispatches from China
  • Member Content
    • Shop
  • Contact Us
    • About us
Nairobi Business Monthly
Home»Companies»Pharmacy board approves Janssen’s prostate cancer drug for early stage therapy
Companies

Pharmacy board approves Janssen’s prostate cancer drug for early stage therapy

NBM CORRESPONDENTBy NBM CORRESPONDENT11th September 2019Updated:23rd September 2019No Comments4 Mins Read
Facebook Twitter WhatsApp Telegram Email
(L-R) Janssen Pharmaceutical country manager Marseille Onyango, Johnson & Johnson government affairs & policy East Africa Director Idah Asin, Dr. Idir Ouzaid, Urologist at Bichat Claude Bernard Hospital and Janssen Kenya medical affairs manager Dr. Eric Muchangi during Janssen Kenya’s Medical Education Symposium on Prostate Cancer.
Share
Facebook Twitter WhatsApp Telegram Email

The local pharmaceuticals regulator, has approved the use of Janssen’s once-daily medication ZYTIGA® (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer ahead of a chemotherapy regime. 

The approval is expected to help boost ongoing efforts to minimise existing barriers to cancer care access.

The prescription only innovator (non generic) oncological management drug is distributed locally by Janssen Kenya as part of the global pharmaceutical firm’s commitment to enhance access of essential drugs.

The Nairobi Law Monthly September Edition

Confirming the recent approval, Janssen Kenya country manager Mr Marseille Onyango said prior to the approval, ZYTIGA had only been licensed for treatment of advanced prostate cancer cases post chemotherapy.

Onyango, while addressing medical professionals at a Nairobi hotel confirmed that ZYTIGA had progressively received international recognition as a broad indication treatment drug for prostate cancer.

“Globally, Janssen Pharmaceutical is dedicated to delivering therapeutic options with exceptional services, Onyango said.

Earlier this year, Janssen Kenya had also received the nod from the National Hospital Insurance Fund (NHIF), which has listed ZYTIGA as a reimbursable innovator drug as part of a joint commitment by the two firms to enhance access of the crucial drug for local prostate cancer patients.

“The local approval by the Pharmacy and Poisons Board, for what we call in clinical terms; an expanded indication for ZYTIGA, helps fill a critical medical need, providing local physicians with an important tool for treating men with metastatic castration-resistant prostate cancer who have not received chemotherapy,” said Onyango, adding that, “Under the Janssen Kenya Prostate cancer program in conjunction with Axios International, a specialised healthcare access company, ZYTIGA will continue being available for all patients including NHIF members who enjoy significant cost savings.”

On his part, Janssen Kenya country medical affairs manager Dr Eric Muchangi expressed optimism that the drug will provide much needed relief for prostate cancer patients and their families.

“ZYTIGA works by inhibiting the enzyme complex required for the production of androgens in the testes, adrenals and the prostate tumor tissue. Having ZYTIGA as a new therapeutic option in Kenya, before chemotherapy will provide hope for patients with metastatic castration-resistant prostate cancer and their families as they continue to battle the disease,” Dr Muchangi said.

Earlier this year, NHIF Claims and Benefits manager, Mrs Judy Otele, had disclosed that with the Janssen Kenya Prostate cancer project, NHIF, had successfully managed to negotiate the price reduction of ZYTIGA from Sh200, 000 to about Sh100, 000. 

There are 40,000 new cases annually and approximately 28,000 cancer related deaths every year. More than 70% of cancer cases are diagnosed at late stage when treatment outcomes are poor

The Janssen Pharmaceutical Companies of Johnson & Johnson is the world’s largest and most broadly based healthcare company. Janssen envisions a world where cancer is a preventable, chronic or curable disease and is focused on developing solutions that prolong and improve patient lives to get there.

To ensure a coordinated response to cancer control in Kenya, the National Cancer Control Strategy (NCCS) 2017-2022 was developed to act as a framework to guide all stakeholders supporting cancer control in Kenya. 

The strategy addresses the whole cancer ecosystem from prevention to survivorship and has 5 pillars namely: Prevention, Early Detection and Screening, Diagnosis, Registration and Surveillance, Treatment, Palliative Care and Survivorship, Coordination, Partnership and Financing and Monitoring, Evaluation and Research. 

Cancer is one of the major non-communicable diseases in Kenya and ranks third as a cause of death after infectious diseases and cardiovascular diseases.
It is estimated that there are 40,000 new cases annually and approximately 28,000 cancer related deaths every year. More than 70% of cancer cases are diagnosed at late stage when treatment outcomes are poor and
palliative care is usually the only management amenable. 

Currently, the NHIF care package entails up to 10 chemotherapy sessions, oral and injectable anti-cancers drugs, inpatient and outpatient oncology services, 20 sessions for radio therapy, and up to two sessions for Brachytherapy for advanced cancer, per year. Among the health facilities that offer the package include some level five and six hospitals, and selected private hospitals in urban centres.

NHIF covers six sessions for the first line treatment for up to Sh25, 000 per session, four sessions for the second and third line treatment for up to Sh150, 000 per session and 20 sessions of radiotherapy at Sh3, 600 per session. Biopsy is covered under the surgical package. Radiology is also done during the diagnosis stage, and this includes MRIs, ultrasounds, or CT scan and PET scan, also covered by NHIF. 

The Nairobi Law Monthly September Edition
Follow on Facebook Follow on X (Twitter) Follow on WhatsApp
Share. Facebook Twitter WhatsApp Telegram
NBM CORRESPONDENT

Related Posts

BAT Kenya records profit in 2024

24th February 2025

Kenya Airways and Air India agreement to elevate tourism and trade

3rd February 2025

CMC driving out of East African vehicle market

20th January 2025

Amsons takes lead in Bamburi Cement acquisition

19th December 2024
Add A Comment

Leave A Reply Cancel Reply

The Nairobi Law Monthly September Edition
Latest Posts

Kenya in fresh IMF talks amid fears of return to austerity

12th June 2025

Kenya Airways total debt records an increase

12th June 2025

Kenya, China sign $1bn deal for infrastructure and jobs

12th June 2025

Kenya bars foreign bidders from state contracts below Sh3 billion

11th June 2025

Off-grid homes at risk as Kenya plans 16% solar tax

11th June 2025
The Nairobi Law Monthly September Edition
Nairobi Business Monthly
Facebook X (Twitter) Instagram LinkedIn
  • About Us
  • Member Content
  • Download Magazine
  • Contact Us
  • Privacy policy
© 2025 NairobiBusinessMonthly. Designed by Okii

Type above and press Enter to search. Press Esc to cancel.